ENMD-2076
CAT:
804-HY-10987A-02
Size:
10 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
ENMD-2076
- CAS Number: 934353-76-1
- UNSPSC Description: ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
- Target Antigen: Apoptosis; Aurora Kinase; FGFR; FLT3; PDGFR; Src; VEGFR
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Epigenetics;Protein Tyrosine Kinase/RTK
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/enmd-2076.html
- Purity: 99.12
- Solubility: DMSO : ≥ 31 mg/mL
- Smiles: CC1=CC(NC2=NC(/C=C/C3=CC=CC=C3)=NC(N4CCN(CC4)C)=C2)=NN1
- Molecular Weight: 375.47
- References & Citations: [1]Fletcher GC, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011 Jan;10(1):126-37.|[2]Wang X, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010 Aug;150(3):313-25.Am J Pathol. 2019 Oct;189(10):2090-2101. |Int J Gynecol Cancer. 2017 Oct;27(8):1666-1674. |Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Am J Pathol. 2019 Oct;189(10):2090-2101.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: Phase 2